Allostery Investments LP Invests $998,000 in Context Therapeutics Inc. (NASDAQ:CNTX)

Allostery Investments LP acquired a new stake in Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 950,166 shares of the company's stock, valued at approximately $998,000. Context Therapeutics accounts for about 1.0% of Allostery Investments LP's portfolio, making the stock its 17th largest position. Allostery Investments LP owned about 1.27% of Context Therapeutics at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Jane Street Group LLC bought a new position in shares of Context Therapeutics during the 4th quarter worth approximately $29,000. Clear Harbor Asset Management LLC increased its holdings in shares of Context Therapeutics by 60.6% in the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock valued at $61,000 after purchasing an additional 21,804 shares during the last quarter. Landscape Capital Management L.L.C. bought a new position in shares of Context Therapeutics in the fourth quarter valued at about $94,000. Walleye Capital LLC lifted its stake in shares of Context Therapeutics by 51.7% during the 4th quarter. Walleye Capital LLC now owns 166,306 shares of the company's stock worth $175,000 after buying an additional 56,651 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Context Therapeutics during the 4th quarter worth about $213,000. Institutional investors and hedge funds own 14.03% of the company's stock.

Context Therapeutics Stock Down 3.5 %

Shares of CNTX stock traded down $0.03 during mid-day trading on Wednesday, reaching $0.78. 19,453 shares of the stock traded hands, compared to its average volume of 296,902. The stock's fifty day simple moving average is $0.78 and its two-hundred day simple moving average is $1.15. Context Therapeutics Inc. has a 1-year low of $0.55 and a 1-year high of $2.75. The company has a market cap of $69.88 million, a price-to-earnings ratio of -0.89 and a beta of 2.11.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01. On average, equities research analysts anticipate that Context Therapeutics Inc. will post -0.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. JMP Securities started coverage on shares of Context Therapeutics in a research report on Wednesday, January 8th. They set an "outperform" rating and a $4.00 price objective for the company. D. Boral Capital reaffirmed a "buy" rating and issued a $9.00 price objective on shares of Context Therapeutics in a report on Tuesday, April 29th. Citizens Jmp raised Context Therapeutics to a "strong-buy" rating in a report on Wednesday, January 8th. HC Wainwright restated a "buy" rating and set a $5.00 price objective on shares of Context Therapeutics in a research note on Friday, March 21st. Finally, William Blair reiterated an "outperform" rating on shares of Context Therapeutics in a research report on Tuesday, April 29th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $6.17.

Context Therapeutics Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.